Top Gum Industries Ltd.

Investor Presentation • May 28, 2025

Q1 2025 REPORT

May 28, 2025

The information included under this presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer to purchase securities and/or an invitation to make offers for their purchase or solicitation of any of the above regarding any securities of Top Gum Industries Ltd. (the "Company") and should not be regarded as a recommendation or an opinion. Any such offer or sale will be made on the basis of a prospectus published by the Company after receiving a permit from the Securities Authority and approval from the Tel Aviv Stock Exchange (hereinafter, respectively: "Securities Authority" and "the Stock Exchange").

This presentation does not purport to encompass or contain any information that may be relevant for the purpose of making any decision regarding an investment in the Company's securities and generally. This presentation does not replace independent data collection and analysis, it should be bear in mind that past data does not necessarily indicate future performance. The presentation includes data and statistics and other publications published by third parties, the content of which has not been independently verified by the Company. The presentation was made, for a convenient and concise presentation, and it does not exhaust the full data about the company and its activities and does

not replace the need to perform a full due diligence. The information contained in this presentation is incomplete and all that is stated in it is subject to a full due diligence and is not a substitute for reviewing reports published by the Company to the public and especially in the draft prospectus or final company prospectus, supplementary prospectus and shelf prospectus. The information under this Presentation is not a substitute for public Information and in the event of any conflict between the content of this presentation and the content of any public Information, the content of the Public Information shall prevail. The information in this Presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be made on the fairness, accuracy, completeness or correctness of the information or opinions contained herein. No legally binding obligations may be created, implied, or inferred from this Presentation. Various statements in this presentation include information which derives from forecasts, estimates, assessments, and other information pertaining to future events and/or matters, the materialization of which is uncertain and beyond the Company's control, and which constitute "forwardlooking information", as defined under the Israeli Securities Law, 1968. Forward-looking statements include descriptions regarding the intent,

belief, or current expectations of the Company and are not guaranteeing future results, performance, or achievements and are based on current expectations, estimations, and assumptions, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performances, or achievements of the Company may differ materially from what is or may be expressed or implied in this presentation due to a variety of factors, many of which are beyond the Company's control, including, without limitation, certain risk factors. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events, or otherwise. Certain information and factual statements (including relating to markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources, and therefore the accuracy of such information and the assumptions on which such information is based has not been independently verified. Nothing in this presentation constitutes tax or business advice and does not constitute a substitute consulting appropriate advisors in these aspects. Every potential investor should seek advice and guidance in connection with potential investments, including tax advice is given such investor tax status.

GROWTH AHEAD

USD 200M; 20% EBITDA

Horizon 2

Horizon 3 Pharma Gummies Pioneer

Horizon 1 >USD 100M; ~16% EBITDA

Q1 2025 HIGHLIGHTS

Best Ever Supplements Q1 USD 9.8M; 57% of Total Sales; +12% QoQ

All Time Revenue Record USD 17.2M; +17% QoQ

Adjusted EBITDA USD 2.5M; +5% QoQ

Institutional Investors Stock Option Exercise ~USD 6.8M

Successful

FDA Audit

Completion

New Product Launch OMG3!

RECORD BACKLOG

• A continued strong increase in year-over-year customers' orders backlog of dietary supplements
• · Together with Island Abbey's backlog, the company's orders backlog for Q1 2025 has more than doubled

Strong supporting NPD pipeline

STRATEGIC PIVOTS

INNOVATIVE DELIVERY SYSTEM

Highest standards of nutraceuticals in the industry

Differentiated Matrix

GUMMICEUTICALS™ Truly sugar-free/No-added sugar | Prebiotic effect Organic (fiber or sugar based) | Unique fibers matrix

Organoleptic Experience

Flavor | Color | Texture | Odor | Shape High-resistance melting point Clean label ingredients

High Dosage

Highest dosage per one gummy without affecting the flavor Awarded winning products

Improved Functionality

Micro-encapsulation Masks flavors | Slow-release | Improves stability | Targeted release Enables new active ingredients | Preserves potency

EXCELLENT LAUNCH IN

Vitafoods Europe Honey Guan

by TopGum

VITAFOODS TASTING CENTRE AWARDS 2023

BEST TASTING FUNCTIONAL FOOD

This certificate is presented to

HoneyGum

TopGum

Natasha Berrow, Executive Vice President - Food

NEW FACILITY IN FINAL STAGES

ISLAND ABBEY POST-ACQUISITION STATUS

• · PMI in full steam, with all functional integration streams in process
• · North American commercial operations consolidated under Dean Williams, CEO of Island Abbey
• · Synergies realization started in all identified strategic areas

			Q1 2025 Q1 2024 QoQ Change
Revenue	17,273	14,760	2,513
Cost of sales	11,548	9,699	1,849
Gross profit	5,725	5,061	664
% from sales	33.1%	34.3%	-1.1%
R&D	799	723	76
S&M	1,681	1,195	486
G&A	1,744	1,809	(65)
Operating profits	1,501	1,334	167
% from sales	8.7%	9.0%	-0.3%
Finance expenses (Income), net	21	(194)	215
Profit before tax	1,480	1,528	(48)
Tax expenses	272	236	36
Net profits	1,208	1,292	(84)
EBILDA	2,123	1,912	211
Adjusted EBITDA	2,513	2,391	122
% from sales	14.5%	16.2%	-1.7%

Non-GAAP EBITDA excludes one-time expenses from ESOP grants and bonuses to employees regarding IPO / Equity transactions

59 502 ,	48 649 ,
64 258 ,	60 265 ,
123 760 ,	108 914 ,
30 580 ,	16 223 ,
30 210 ,	24 295 ,
60 790 ,	40 518 ,
3 078 ,	3 062 ,
56 946 ,	56 631 ,
(131)	(938)
3 077 ,	9 641 ,
62 970 ,	68 396 ,

123,760 108,914

Thank you